



MARKET RELEASE

18 February 2013

Bioxyne Limited

TRADING HALT

The securities of Bioxyne Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Wednesday, 20 February 2013 or when the announcement is released to the market.

Security Code: BXN

Kimberley Brown
Senior Adviser, Listings Compliance (Sydney)

Ms Kimberley Brown
Senior Adviser, Listing
Australian Securities Exchange Limited
Companies Announcements Office
SYDNEY

18 February 2013

REQUEST FOR TRADING HALT

In accordance with ASX Listing Rule 17.1, Bioxyne Limited ("Bioxyne" or the "Company") requests the granting of a trading halt on Bioxyne's ordinary securities (ASX code: BXN) from quotation on the ASX, with effect immediately prior to the commencement of trading on Monday 18 February 2013.

The basis for this request for trading halt is that, as announced earlier today:

- (a) the Company has entered into a conditional non-binding term sheet in relation to the proposed acquisition of 100% of the securities in Vitality Devices Pty Limited and the proposed investment by Bioxyne's major shareholder, Phillip Asset Management Limited as trustee for IB Australian Bioscience Fund I, of up to \$2.5 million into the resulting merged business of the Company; and
- (b) as a condition of that proposed transaction, the Company will be undertaking an underwritten share placement of up to 15% of the total issued ordinary capital of the Company to assist in funding transaction costs ("Placement").

Bioxyne seeks for the trading halt to continue until immediately after the completion of the Placement, which is currently expected to complete by close of business, Tuesday 19 February 2013.

The Company is not aware of any reason why a trading halt should not be granted and further confirms that it is not aware of any other information necessary to inform the market about the requested trading halt.

Yours faithfully



Laura Raymer
Company Secretary
Bioxyne Ltd